- Quarter end
- 31 Mar 2025
- the date the book describes
- Filed
- 5 Nov 2026
- latest of these filings; the earliest 12 May 2025
- Managers listing it
- 29
- at least, of 95 tracked, among listed positions
- Comparable managers
- 95
- filed both Q4 2024 and Q1 2025; 22 listed it in both
- Shares listed
- 282,001,902
- combined, among listed positions
- Reported value
- $19.1bn
- combined, at the quarter end
Among the 95 comparable managers: 20 buyers (opened or added shares) and 10 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing CVS in Q1 2025
29 of 29 holders
Largest increases and reductions, by shares
Increases
- Capital Research Global Investorsexisting position · 18,726,297 shares now+16,220,891
- Capital World Investorsexisting position · 68,398,405 shares now+7,358,628
- Dodge & Coxexisting position · 73,459,122 shares now+3,353,223
- Holocene Advisors LPexisting position · 5,928,174 shares now+3,292,312
- Marshall Wace LLPexisting position · 3,726,296 shares now+3,041,644
Reductions
- Susquehanna International Group LLPexisting position · 2,150,009 shares now-1,890,558
- Balyasny Asset Management LLCexisting position · 1,160,420 shares now-665,189
- Millennium Management LLCexisting position · 3,728,991 shares now-462,584
- Moore Capital Management LPexisting position · 140,000 shares now-336,569
- Citadel Advisors LLCexisting position · 6,260,250 shares now-106,195
New positions and exits
New (1)
- Winton Group Ltd$947k
Exited (2)
- Voloridge Investment Management LLCwas $41m
- Two Sigma Advisers LPwas $38m
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2013 | 19 | $12.0bn | n.a. | n.a. |
| Q3 2013 | 22 | $11.8bn | n.a. | n.a. |
| Q4 2013 | 19 | $14.0bn | n.a. | n.a. |
| Q1 2014 | 17 | $15.3bn | n.a. | n.a. |
| Q2 2014 | 24 | $14.7bn | n.a. | n.a. |
| Q3 2014 | 21 | $15.4bn | n.a. | n.a. |
| Q4 2014 | 24 | $18.3bn | n.a. | n.a. |
| Q1 2015 | 25 | $19.7bn | n.a. | n.a. |
| Q2 2015 | 24 | $20.2bn | n.a. | n.a. |
| Q3 2015 | 30 | $19.0bn | n.a. | n.a. |
| Q4 2015 | 25 | $17.8bn | n.a. | n.a. |
| Q1 2016 | 24 | $17.1bn | n.a. | n.a. |
| Q2 2016 | 34 | $14.3bn | n.a. | n.a. |
| Q3 2016 | 30 | $12.8bn | n.a. | n.a. |
| Q4 2016 | 32 | $9.3bn | n.a. | n.a. |
| Q1 2017 | 29 | $8.7bn | n.a. | n.a. |
| Q2 2017 | 20 | $9.0bn | n.a. | n.a. |
| Q3 2017 | 23 | $9.4bn | n.a. | n.a. |
| Q4 2017 | 32 | $10.5bn | n.a. | n.a. |
| Q1 2018 | 31 | $8.7bn | n.a. | n.a. |
| Q2 2018 | 21 | $8.1bn | n.a. | n.a. |
| Q3 2018 | 25 | $10.7bn | n.a. | n.a. |
| Q4 2018 | 33 | $11.4bn | n.a. | n.a. |
| Q1 2019 | 27 | $8.5bn | n.a. | n.a. |
| Q2 2019 | 25 | $8.0bn | n.a. | n.a. |
| Q3 2019 | 25 | $9.6bn | n.a. | n.a. |
| Q4 2019 | 27 | $11.4bn | n.a. | n.a. |
| Q1 2020 | 29 | $8.1bn | n.a. | n.a. |
| Q2 2020 | 26 | $9.3bn | n.a. | n.a. |
| Q3 2020 | 29 | $8.9bn | n.a. | n.a. |
| Q4 2020 | 22 | $9.8bn | n.a. | n.a. |
| Q1 2021 | 28 | $10.3bn | n.a. | n.a. |
| Q2 2021 | 24 | $11.8bn | n.a. | n.a. |
| Q3 2021 | 28 | $11.9bn | n.a. | n.a. |
| Q4 2021 | 28 | $14.7bn | n.a. | n.a. |
| Q1 2022 | 25 | $14.4bn | n.a. | n.a. |
| Q2 2022 | 30 | $13.5bn | n.a. | n.a. |
| Q3 2022 | 28 | $13.9bn | n.a. | n.a. |
| Q4 2022 | 30 | $12.6bn | n.a. | n.a. |
| Q1 2023 | 36 | $9.6bn | n.a. | n.a. |
| Q2 2023 | 33 | $9.8bn | n.a. | n.a. |
| Q3 2023 | 33 | $11.7bn | n.a. | n.a. |
| Q4 2023 | 32 | $14.2bn | 15 | 18 |
| Q1 2024 | 21 | $14.3bn | 9 | 14 |
| Q2 2024 | 24 | $14.2bn | 16 | 8 |
| Q3 2024 | 31 | $14.2bn | 23 | 10 |
| Q4 2024 | 32 | $11.0bn | 17 | 16 |
| Q1 2025 | 29 | $19.1bn | 20 | 10 |
| Q2 2025 | 31 | $19.6bn | 19 | 12 |
| Q3 2025 | 28 | $21.9bn | 16 | 11 |
| Q4 2025 | 29 | $22.8bn | 18 | 23 |
| Q1 2026 | 32 | $21.1bn | 24 | 20 |
| Q2 2026 | 31 | $30.8bn | 18 | 24 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
CVS and PM →CVS and KO →CVS and COST →Choose a stock to compare with CVS →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own CVS, latest filings →Back to the 13F Explorer →